Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.

Annals of Saudi medicine - 1 Jan 2000

Sahin Ahmet, Akay Ozlem

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) can cause chronic liver disease, hepatic cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Early diagnosis and treatment are thus vital. OBJECTIVES: We aimed to investigate the sustained virological response (SVR) rates in chronic hepatitis C patients infected with different genotypes, receiving different direct-acting antiviral treatments (DAAs). DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Liver Neoplasms

Share to Ribavirin

Share to Ritonavir

Share to Turkey

Source

Open in PubMed Open full text

Identifiers

PMID: 37805816
DOI: 10.5144/0256-4947.2023.308
PMCID: PMC10560371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.PMID 37805816Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.Semantic proximity Read ↗

Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.Semantic proximity Read ↗

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.Semantic proximity Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.Semantic proximity Read ↗

Update on the treatment of hepatitis C genotypes 2-6.Semantic proximity Read ↗

Direct-Acting Antiviral Therapy in HCV Patients: A Retrospective Study of the Pre- and Post-Treatment Impact in Saudi ArabiaSemantic proximity Read ↗

Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia.Semantic proximity Read ↗

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.Semantic proximity Read ↗

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.